^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RAD54L (DNA Repair And Recombination Protein RAD54)

    i
    Apply
    A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (NCT04826341)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/20/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2027
    BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)
    Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) (NCT05700721)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/02/2023
    Primary completion :
    08/07/2025
    Completion :
    08/07/2027
    PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52
    |
    PD-L1 expression
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Pembrolizumab, Olaparib, and Temozolomide for People with Glioma (NCT05188508)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    01/14/2022
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide
    Niraparib in Tumors Metastatic to the CNS (NCT04992013)
    Phase 2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    12/12/2024
    Initiation :
    04/05/2022
    Primary completion :
    12/01/2025
    Completion :
    06/01/2027
    BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3
    |
    HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    Zejula (niraparib)
    Niraparib As First Line Therapy with Metastatic Homologous Repair-deficient Pancreatic Cancer (PARPi-PANC) (NCT05442749)
    Phase 2
    Centre Leon Berard
    Withdrawn
    Last update posted :
    09/11/2024
    Initiation :
    10/28/2022
    Primary completion :
    01/15/2026
    Completion :
    09/15/2026
    BRCA1 • BRCA2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • FANCD2
    |
    Zejula (niraparib)
    High-Risk Metachronous Oligometastatic Prostate Cancer Trial (KNIGHTS) (NCT06212583)
    Phase 2
    University of Maryland, Baltimore
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    04/17/2024
    Primary completion :
    12/31/2028
    Completion :
    12/31/2029
    TP53 • BRCA1 • CHEK2 • RAD51B • RAD54L
    |
    ATM mutation • PALB2 mutation
    |
    Zejula (niraparib) • abiraterone acetate • prednisone
    A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer (BrUOG 360) (NCT04253262)
    Phase 1/2
    Brown University
    Active, not recruiting
    Last update posted :
    04/05/2024
    Initiation :
    04/03/2020
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    BRCA1 • BRCA2 • HRD • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    BRIP1 mutation
    |
    Rubraca (rucaparib) • Aliqopa (copanlisib)
    I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX) (NCT05986071)
    Phase 1/2
    Institut Paoli-Calmettes
    Not yet recruiting
    Last update posted :
    03/29/2024
    Initiation :
    05/01/2024
    Primary completion :
    04/01/2027
    Completion :
    10/15/2027
    HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1
    |
    HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation
    |
    fulvestrant • tuvusertib (M1774)
    Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) (NCT04276376)
    Phase 2
    Gustave Roussy, Cancer Campus, Grand Paris
    Suspended
    Last update posted :
    03/26/2024
    Initiation :
    04/12/2019
    Primary completion :
    12/01/2024
    Completion :
    04/01/2025
    BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • IL2 • RAD51D • BARD1 • NBN • RAD54L • DRD
    |
    DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD
    |
    Tecentriq (atezolizumab) • Rubraca (rucaparib)
    Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO) (NCT04779151)
    Phase 2
    Gustave Roussy, Cancer Campus, Grand Paris
    Suspended
    Last update posted :
    03/26/2024
    Initiation :
    04/07/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2027
    HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD
    |
    HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    03/06/2024
    Initiation :
    04/26/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • BAP1 • CDK12 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation
    |
    Talzenna (talazoparib)
    Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID) (NCT03786796)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    03/05/2024
    Initiation :
    06/03/2019
    Primary completion :
    03/01/2025
    Completion :
    03/01/2026
    BRCA1 • BRCA2 • BAP1 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    Lynparza (olaparib)
    Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF) (NCT04053322)
    Phase 2
    UNICANCER
    Active, not recruiting
    Last update posted :
    02/05/2024
    Initiation :
    08/26/2019
    Primary completion :
    11/15/2023
    Completion :
    08/01/2027
    HER-2 • ER • BRCA1 • BRCA2 • MSI • CDK12 • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • CHEK1 • BARD1 • NBN • RAD54L • FANCL • PPP2R2A
    |
    ER positive • BRCA1 mutation • HER-2 negative • FANCA deletion
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • fulvestrant
    Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects (SUKSES-B2) (NCT04939662)
    Phase 2
    Se-Hoon Lee
    Completed
    Last update posted :
    01/01/2024
    Initiation :
    06/11/2021
    Primary completion :
    10/27/2023
    Completion :
    10/27/2023
    BRCA1 • BRCA2 • SLFN11 • BRCA • RAD51 • RAD51B • RAD51C • RAD50 • NBN • RAD54L • WRN • POU2F3 • RAD52 • RECQL5 • RECQL • RECQL4 • RPA1
    |
    RAD51C mutation • RAD51D mutation • RAD51B mutation • BRCA mutation • RAD54L mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib)
    Niraparib and Dostarlimab in HRD Solid Tumors (DIDO) (NCT04983745)
    Phase 2
    West Cancer Center
    Recruiting
    Last update posted :
    12/21/2023
    Initiation :
    11/29/2021
    Primary completion :
    08/01/2024
    Completion :
    08/01/2025
    BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A • FANCI
    |
    BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations (NCT03448718)
    Phase 2
    Matthew Galsky
    Completed
    Last update posted :
    11/22/2023
    Initiation :
    04/17/2018
    Primary completion :
    07/14/2021
    Completion :
    10/15/2021
    BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3
    |
    Lynparza (olaparib)
    Carboplatin or Olaparib for BRcA Deficient Prostate Cancer (BRACeD) (NCT04038502)
    Phase 2
    VA Office of Research and Development
    Recruiting
    Last update posted :
    11/01/2023
    Initiation :
    10/01/2019
    Primary completion :
    08/30/2024
    Completion :
    08/29/2025
    RAD51B • RAD51C • RAD51D • RAD54L
    |
    ATRX mutation • RAD54L mutation • RAD51 mutation
    |
    Lynparza (olaparib) • carboplatin
    The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation (PROact) (NCT05167175)
    Phase 2
    Hongqian Guo
    Recruiting
    Last update posted :
    10/25/2022
    Initiation :
    03/01/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    Lynparza (olaparib) • abiraterone acetate • prednisone
    The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer (NCT05461261)
    Phase 2
    The Affiliated Nanjing Drum Tower Hospital of N...
    Recruiting
    Last update posted :
    10/24/2022
    Initiation :
    07/01/2022
    Primary completion :
    06/30/2025
    Completion :
    12/31/2025
    BRCA1 • BRCA2 • ATM • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    cisplatin • carboplatin • docetaxel
    To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA) (NCT02476968)
    Phase 4
    AstraZeneca
    Completed
    Last update posted :
    09/10/2022
    Initiation :
    09/28/2015
    Primary completion :
    04/17/2020
    Completion :
    12/17/2021
    BRCA1 • BRCA2 • CDK12 • BRCA • MUC16 • CHEK2 • RAD51B • BRIP1 • RAD51C • CHEK1 • RAD54L • FANCL • PPP2R2A
    |
    BRCA2 mutation • BRCA1 mutation • CHEK2 mutation • RAD51B mutation • BARD1 mutation • BRCA mutation
    |
    Lynparza (olaparib)
    Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency (NCT04892693)
    Phase 2
    Seoul National University Hospital
    Recruiting
    Last update posted :
    09/02/2022
    Initiation :
    05/25/2021
    Primary completion :
    05/10/2023
    Completion :
    05/10/2025
    BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Talzenna (talazoparib)
    The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation (PROspect) (NCT05262608)
    Phase 2
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Un...
    Recruiting
    Last update posted :
    03/02/2022
    Initiation :
    12/07/2021
    Primary completion :
    02/26/2024
    Completion :
    04/26/2024
    BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    Lynparza (olaparib)
    Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi) (NCT05116579)
    Phase N/A
    Sun Yat-sen University
    Recruiting
    Last update posted :
    11/11/2021
    Initiation :
    10/31/2021
    Primary completion :
    03/31/2023
    Completion :
    08/31/2023
    BRCA1 • BRCA2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation • BRCA1 mutation + ATM mutation • CHEK1 expression
    Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With HRR Mutation and MSS (NCT04592211)
    Phase 1/2
    Yonsei University
    Not yet recruiting
    Last update posted :
    08/31/2021
    Initiation :
    10/01/2021
    Primary completion :
    12/31/2022
    Completion :
    05/31/2023
    HER-2 • BRCA1 • BRCA2 • HRD • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • paclitaxel
    Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) (NCT03377556)
    Phase 2
    Southwest Oncology Group
    Completed
    Last update posted :
    06/23/2021
    Initiation :
    03/03/2017
    Primary completion :
    01/10/2021
    Completion :
    04/16/2021
    BRCA1 • BRCA2 • HRD • PALB2 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCM • FANCD2 • RPA1 • FANCC
    |
    BARD1 mutation • RPA1 mutation
    |
    Talzenna (talazoparib)
    Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair (NCT03318445)
    Phase 1
    Pamela Munster
    Completed
    Last update posted :
    03/04/2021
    Initiation :
    01/12/2018
    Primary completion :
    03/01/2021
    Completion :
    03/01/2021
    BRCA1 • BRCA2 • CDK12 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L
    |
    Rubraca (rucaparib) • irinotecan
    Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations (SUKSES-B) (NCT03009682)
    Phase 2
    Samsung Medical Center
    Completed
    Last update posted :
    02/18/2021
    Initiation :
    08/01/2016
    Primary completion :
    01/01/2021
    Completion :
    01/01/2021
    BRCA1 • BRCA2 • ATM • RAD51 • RAD51B • RAD51C • RAD50 • NBN • RAD54L • WRN • RAD52 • RECQL5 • RECQL • RECQL4 • RPA1
    |
    BRCA2 mutation • BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • BLM mutation • MRE11A mutation • RAD54L mutation • NBN mutation • WRN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation • RPA1 mutation
    |
    Lynparza (olaparib)
    Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response (NCT04692662)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    01/12/2021
    Initiation :
    01/15/2021
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • CDK12 • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • FANCF mutation • FANCG mutation
    |
    Talzenna (talazoparib)